Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRAKE-AF: Ivabradine vs Digoxin in Permanent Atrial Fibrillation
NCT03718273Phase 3Completed
- Start
- Oct 2018
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ivabradine in Atrial fibrillation (AFib) (2 arms). Primary endpoints: Heart rate reduction at 3 months and Serious adverse events at 3 months. Started Oct 2018; status: completed.
02
Drugs
ivabradine
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT03718273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03718273.